CFRA reiterates Sell rating on Rivian stock amid narrowed guidance

Rivian reported Q3 deliveries of 13,201 vehicles, a 32% year-over-year increase that surpassed some consensus estimates but fell short of CFRA's forecast, while production of 10,720 units indicated significantly lower inventory levels as deliveries outpaced manufacturing. The company also narrowed its 2025 sales guidance, leading CFRA to maintain a "Sell" rating and lower EPS estimates, citing ongoing cash burn concerns and potential free cash flow strain from the new Georgia plant, further complicated by a recent NHTSA preliminary evaluation into its delivery van seat belts.

Analysis

Rivian's third-quarter results present a mixed operational and financial picture, creating divergent analyst sentiment. The company reported a 32% year-over-year increase in deliveries to 13,201 vehicles, a figure that surpassed the Visible Alpha Consensus estimate of 12,690 but fell short of CFRA's 14,000-unit forecast. Production of 10,720 units, while beating consensus, represented a 19% decrease, and for the second consecutive quarter, deliveries significantly outpaced manufacturing, indicating a substantial inventory drawdown. This performance was followed by a narrowing of full-year 2025 delivery guidance, reducing the midpoint by 500 vehicles. Consequently, CFRA maintained its 'Sell' rating and an $8.00 price target, lowering its 2025-2026 EPS estimates and citing significant concerns over cash burn and the potential for the new Georgia plant to further strain free cash flow. While InvestingPro data highlights a healthy balance sheet with more cash than debt and a current ratio of 3.44, the bearish outlook is compounded by a new preliminary NHTSA investigation into seat belt performance in 17,198 of its delivery vans, adding a layer of regulatory risk to the existing operational and financial pressures.

Key Decisions for Investors

• Investors should closely monitor Rivian's cash burn rate and production figures, as the reliance on inventory to meet delivery targets and the capital outlay for the Georgia plant represent significant financial and operational risks.
• Given the conflicting analyst ratings, with CFRA issuing a 'Sell' rating and an $8.00 price target against the stock's $13.58 price, it is prudent to weigh the substantial downside risk before initiating or adding to a position.
• The preliminary NHTSA investigation into delivery van seat belts introduces a new regulatory overhang that could lead to unforeseen costs or production impacts, warranting a cautious stance until the scope and financial implications become clearer.